[go: up one dir, main page]

MX2020011756A - Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. - Google Patents

Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.

Info

Publication number
MX2020011756A
MX2020011756A MX2020011756A MX2020011756A MX2020011756A MX 2020011756 A MX2020011756 A MX 2020011756A MX 2020011756 A MX2020011756 A MX 2020011756A MX 2020011756 A MX2020011756 A MX 2020011756A MX 2020011756 A MX2020011756 A MX 2020011756A
Authority
MX
Mexico
Prior art keywords
salts
making
methods
same
formulations
Prior art date
Application number
MX2020011756A
Other languages
English (en)
Inventor
Fritz Blatter
Yuan Liu
Wei Zhang
Manshiu Leung
Markus Frieser
Karthik Nagapudi
Ludwig Pilsl
Shuai Wang
Srikonda Sastry
Ramachandran Radhakrishnan
Roland Muller
Christine Czauderna
Lawrence Emerson Fisher
Rajendra S Tandale
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2020011756A publication Critical patent/MX2020011756A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan sales, hidratos y solvatos del Compuesto I y métodos para hacer y usar el mismo y las formas de dosificación relacionadas del mismo.
MX2020011756A 2018-02-02 2020-07-30 Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. MX2020011756A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018075023 2018-02-02

Publications (1)

Publication Number Publication Date
MX2020011756A true MX2020011756A (es) 2021-06-23

Family

ID=65494537

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008076A MX2020008076A (es) 2018-02-02 2019-02-01 Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2020011756A MX2020011756A (es) 2018-02-02 2020-07-30 Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020008076A MX2020008076A (es) 2018-02-02 2019-02-01 Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.

Country Status (18)

Country Link
US (2) US20200361933A1 (es)
EP (1) EP3746441B1 (es)
JP (2) JP7372926B2 (es)
KR (1) KR20200118098A (es)
CN (2) CN117247383A (es)
AR (1) AR114090A1 (es)
AU (2) AU2019215172B2 (es)
BR (1) BR112020015759A2 (es)
CA (1) CA3090270A1 (es)
ES (1) ES2949662T3 (es)
HR (1) HRP20230645T1 (es)
IL (2) IL312673A (es)
MX (2) MX2020008076A (es)
PL (1) PL3746441T3 (es)
SG (1) SG11202007726RA (es)
SI (1) SI3746441T1 (es)
TW (2) TW202426448A (es)
WO (1) WO2019152863A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293474A (en) 2019-12-04 2022-08-01 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用
CN116509850A (zh) * 2022-01-21 2023-08-01 苏州爱科百发生物医药技术有限公司 N-芳基吡啶酮类化合物在尘肺治疗中的用途
EP4524132A1 (en) * 2022-05-10 2025-03-19 Myrodia Therapeutics Co., Ltd. 2-methyl-2-thiazoline salt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303312B6 (cs) 1999-05-07 2012-07-25 Texas Biotechnology Corporation Deriváty karboxylové kyseliny, které inhibují vazbu integrinu na jejich receptory
BRPI0720862A2 (pt) * 2006-12-27 2014-02-25 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos como inibidores de rho-cinase
KR20110114684A (ko) 2009-01-26 2011-10-19 인터뮨, 인크. 급성 심근 경색 및 연관된 질환을 치료하는 방법
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
PT3383397T (pt) * 2015-12-02 2021-11-03 Merck Sharp & Dohme Composições farmacêuticas contendo doravirina, tenofovir disoproxil fumarato e lamivudina

Also Published As

Publication number Publication date
WO2019152863A1 (en) 2019-08-08
ES2949662T3 (es) 2023-10-02
IL276430B1 (en) 2024-06-01
SI3746441T1 (sl) 2023-08-31
SG11202007726RA (en) 2020-09-29
IL276430B2 (en) 2024-10-01
IL276430A (en) 2020-09-30
MX2020008076A (es) 2020-09-24
CN112105616A (zh) 2020-12-18
PL3746441T3 (pl) 2023-07-31
EP3746441B1 (en) 2023-04-05
CN117247383A (zh) 2023-12-19
CA3090270A1 (en) 2019-08-08
AU2019215172A1 (en) 2020-08-20
AU2023222929A1 (en) 2023-09-21
AU2019215172B2 (en) 2023-08-10
TW201940482A (zh) 2019-10-16
KR20200118098A (ko) 2020-10-14
JP2021512118A (ja) 2021-05-13
HRP20230645T1 (hr) 2023-09-29
BR112020015759A2 (pt) 2020-12-08
EP3746441A1 (en) 2020-12-09
US20200361933A1 (en) 2020-11-19
US20240409539A1 (en) 2024-12-12
AR114090A1 (es) 2020-07-22
JP7372926B2 (ja) 2023-11-01
CN112105616B (zh) 2023-09-01
TW202426448A (zh) 2024-07-01
JP2023145680A (ja) 2023-10-11
TWI834634B (zh) 2024-03-11
IL312673A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MX2020011746A (es) Terapias genicas para los trastornos lisosomales.
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
PH12021500014A1 (en) Fused ring compounds
GEP20237506B (en) Pcsk9 antagonist compounds
PH12020550792A1 (en) Compounds useful for inhibiting cdk7
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2022002976A (es) Inhibidores selectivos de jak1.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
CY1122024T1 (el) Ενωσεις αναστολης σηματοδοτησης μονοπατιου notch
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
PH12017501816A1 (en) Azabensimidazoles and their use as amp a receptor modulators
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
PH12020550253A1 (en) Bicyclic compounds for use as rip1 kinase inhibitors
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX2021007201A (es) Producto estable con esta?o para el cuidado oral.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
WO2018211324A8 (en) Prodrugs for the treatment of disease
SG11201900709QA (en) Mixed cement
WO2018096525A3 (en) Heteroaryl compounds and uses thereof
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof